about
CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.Laser-Doppler flowmetry is reliable for early diagnosis of small-bowel acute rejection in the mouse.Accelerated acute rejection of the intestinal graft in CD28-deficient mice.The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection.The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin.Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response.Cutting Edge: Retinoic Acid Signaling in B Cells Is Essential for Oral Immunization and Microflora CompositionDifferential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.Mucosal immunity: implications for vaccine development.Host defense against cholera toxin is strongly CD4+ T cell dependent.Mucosal Vaccine Development Based on Liposome Technology.Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.B-cell-deficient mice develop complete immune protection against genital tract infection with Chlamydia trachomatis.Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans?Induction of gut IgA production through T cell-dependent and T cell-independent pathways.Recent progress in mucosal vaccine development: potential and limitations.The role of Peyer's patches in synchronizing gut IgA responses.The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization.The regulation of gut mucosal IgA B-cell responses: recent developments.Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant.Monoclonal antibodies to cholera toxin with special reference to cross-reactions with Escherichia coli heat-labile enterotoxin.Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.Cholera toxin enhances antigen presentation.Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells.T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions.Antigen-specific and polyclonal CD4+ lamina propria T-cell lines: phenotypic and functional characterization.Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro.The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens.IgA B Cell Responses to Gut Mucosal Antigens: Do We Know it all?Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.The influence of costimulation and regulatory CD4+ T cells on intestinal IgA immune responses.
P50
Q30367547-F2D807D1-9403-45D4-80F9-5E9BDCFC2C44Q30401712-9C345B56-8E65-445E-A0B1-0562F6005016Q30779032-E7490D4A-03CC-4A72-A6CF-F5B3F7552105Q33213653-D45A8591-FE8B-4499-9C87-CA3B9EC88F12Q33747604-1430F230-3AEB-4C0D-B325-0ADDA8768D9FQ34183186-4D2EF61F-BBE4-4303-989D-573C55C1AFBDQ35082439-942C4768-0957-4913-8995-B4A95E12DF2AQ35093806-7ED8C799-E5B1-45F4-8B1B-CB04E13AA667Q35094061-D9B7F566-D6BA-4F7A-91EE-059BF1982497Q35544261-EC5836EB-E705-4F11-AEFF-4FAAB18D5446Q35688668-24AC39DB-4A09-436D-93E4-DD9E9E9A8BB3Q35947252-FEABC31E-628F-463E-AEC5-178A15B23DBEQ36024836-2F4D5946-4986-4C9C-BC7A-ACA18B224BD5Q36064104-ECBDB6B3-8849-4B93-A0AA-622BEF248437Q36117069-3B5450B8-DF2F-4885-A56F-1F160DEBBB6DQ36988065-81CAADA5-EDC2-49BA-9432-AE8BD77D954DQ37581129-C2B4A65C-ADDD-4F39-A8B0-5A4359455ECFQ37789144-E6FC9E40-1C28-4D47-9D07-A528E65844BAQ37835358-BF49D51A-838E-4AF1-9A4E-A25D9683A38DQ37881451-A8443B19-09A0-4B33-969D-81465C79ACAAQ37881794-AA869E7B-3045-4FB8-A32A-469574F681F6Q37977139-117E3220-4E14-49D1-A2C6-1271B9EFD783Q38029250-FEAB6A3A-24CC-4D49-BD90-AC92677678B8Q38062531-568F8AEB-88D0-4535-87B9-BBE2F9187762Q39168847-9FA4EDC9-4298-4938-9B90-6EFCA1268834Q39459081-7CA5BE96-4D91-47C2-8E7D-242A889FB000Q39717371-25F905A3-8BDC-4A3A-9D03-88CBCB3FF60FQ40184439-C394A359-2EBE-418F-980B-ABB473FF74C3Q40762647-D6C8463B-B4DA-4808-8368-22E4C4412979Q40788029-104FD214-B061-463F-B739-C52156B9C5F6Q41348672-8699B1AD-5C65-4B84-B08E-596751444B71Q41405662-F23887DB-16E3-4D86-89B2-C42097782F85Q41561732-A4226986-B4EB-4F25-BCD2-D417C7283D12Q41601098-733562CF-45FC-4358-9E08-7B8B1D0F6EB9Q41649200-F8F0C110-900B-4733-889A-AEDDDD7876B5Q41685667-5AFC544F-70DE-447A-A497-0C8C63D5A3A9Q41915577-EC69FC9A-C571-4F70-967D-D215C699B6F1Q42007827-3D70E17F-E2B6-43C7-86C0-AAAD778DD5F0Q42950246-C0CD5526-2352-479E-AE89-90FC8FD57498Q43088845-57610249-E4A4-4856-8414-2AA732307553
P50
description
Swedish researcher
@en
Zweeds onderzoeker
@nl
svensk forsker
@nb
name
Nils Y. Lycke
@da
Nils Y. Lycke
@de
Nils Y. Lycke
@en
Nils Y. Lycke
@es
Nils Y. Lycke
@fr
Nils Y. Lycke
@nb
Nils Y. Lycke
@nl
Nils Y. Lycke
@nn
Nils Y. Lycke
@sl
Nils Y. Lycke
@sv
type
label
Nils Y. Lycke
@da
Nils Y. Lycke
@de
Nils Y. Lycke
@en
Nils Y. Lycke
@es
Nils Y. Lycke
@fr
Nils Y. Lycke
@nb
Nils Y. Lycke
@nl
Nils Y. Lycke
@nn
Nils Y. Lycke
@sl
Nils Y. Lycke
@sv
altLabel
Nils Lycke
@en
Nils Y Lycke
@en
Nils Yngve Lycke
@en
prefLabel
Nils Y. Lycke
@da
Nils Y. Lycke
@de
Nils Y. Lycke
@en
Nils Y. Lycke
@es
Nils Y. Lycke
@fr
Nils Y. Lycke
@nb
Nils Y. Lycke
@nl
Nils Y. Lycke
@nn
Nils Y. Lycke
@sl
Nils Y. Lycke
@sv
P106
P2038
Nils_Lycke
P21
P27
P31
P496
0000-0003-1155-4861